Science & Technology

This article outlines current U.S. government processes to bolster biosecurity and biosafety measures and summarizes five key findings from biosecurity experts.

Stephen Walt advises that in order to prepare students of public policy schools for a rapidly changing world, faculty should teach historical cases where the prevailing theories led to bad policy choices, and where new ones had to be devised to address a novel set of circumstances. 

Stephen Walt analyzes the priority that the United States should place on competing with China by asking and answering five questions.

Calder Walton recounts how Russia and China are using their intelligence agencies to reverse the outcome of the Cold War

In an interconnected world, cyberattacks are becoming more frequent and sophisticated. Building resilience against this asymmetric threat is critical for countries to protect their economies, critical infrastructure, and democratic institutions. However, cyberattacks do not respect borders, and no country can address this threat alone. The strength and longevity of the transatlantic partnership between the EU and the U.S. presents a unique opportunity to address this strategic threat through international cooperation. Through an analysis of cyberwarfare in the ongoing war in Ukraine, this paper proposes policy recommendations to enhance transatlantic coordination and cooperation against current and future adversaries in a new era of strategic competition. Ultimately, a stronger transatlantic partnership is critical for protecting international democratic norms, building resilience against cyber threats, and strengthening global security and stability.

Neurodegenerative diseases (NDDs) represent a global health emergency, affecting millions of individuals and imposing significant economic burdens. Despite increased funding and government initiatives, effective therapies remain elusive, and NDD research lags behind other fields. This report argues for a simplified, accelerated, and transparent unified approach to NDD research, building on lessons from other fields and industries.

In the last decade, there has been a significant increase in the prevalence of neurodegenerative diseases (NDD) in the United States, affecting approximately 10.5 million individuals. This number is predicted to triple in the next 30 years.¹ However, in comparison to other disease areas such as oncology, the approval of NDD drugs has been relatively limited. Our team has explored the NDD drug development ecosystem from three perspectives: stakeholders, funding, and policy. This article summarizes our key findings and presents a case study to suggest that the scarcity of new drug development may be attributable to insufficient basic scientific research. Finally, we outline our objectives for the upcoming semester.

Stephen Walt offers some brief foreign-policy advice for the newest members of the U.S. legislature.

In recent years, there has been an increased focus on finding treatments for neurodegenerative diseases such as Alzheimer's and Parkinson's, as the prevalence of these diseases continues to rise globally. This blog aims to provide an overview of the sources and trends of funding for neurodegenerative disease research, with a particular focus on comparing funding for these diseases with that of other classes of diseases. By examining historical funding trends and the current sources of funding, we seek to shed light on the current state of the funding ecosystem for neurodegenerative disease research. We will also explore how funding is allocated across different types of neurodegenerative diseases and discuss potential bottlenecks in the funding process that may be hindering progress in the development of therapies.

*This blog is part of a series titled TAPP for Neurodegenerative Diseases Drug Discovery: Mapping the ecosystem

Neurodegenerative diseases (NDDs) are a class of disorders that cause the progressive loss of structure or function of neurons, leading to declines in cognitive and physical abilities. Drug discovery and development for these diseases is a complex, multi-stakeholder process involving a variety of entities across the United States, including government agencies, businesses, research institutions, academic institutions, and non-profit organizations. These stakeholders interact with each other at various stages of the non-linear cycle of drug development, which typically involves a range of activities including pre-clinical research, clinical trials, regulatory approval, and commercialization.

Given the complexity of this process and the challenges involved in developing effective treatments for NDDs, it is important to better understand the role of different stakeholders and the potential barriers they face. This blog aims to provide a deeper examination of the various stakeholders involved in NDD drug discovery and development, and to offer an initial hypothesis on key challenges that may be contributing to the lack of disease-altering therapies for these conditions.

*This blog is part of a series titled TAPP for Neurodegenerative Diseases Drug Discovery: Mapping the ecosystem